(Q47123308)

8 January 2018

title

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma (English)

1 reference

8 January 2018

1 reference

54

Meenhard Herlyn

1 reference

8 January 2018

31

Keith T Flaherty

1 reference

8 January 2018

11

Adina Vultur

1 reference

8 January 2018

1

Clemens Krepler

1 reference

PMC publication ID

5726788

8 January 2018

Katherine L Nathanson

53

Katherine L Nathanson

1 reference

8 January 2018

22

Tara C Gangadhar

1 reference

8 January 2018

Jennifer Wargo

25

Jennifer A Wargo

1 reference

8 January 2018

Gordon B. Mills

28

Gordon B Mills

1 reference

8 January 2018

Giorgos Karakousis

18

Giorgos Karakousis

1 reference

8 January 2018

Nicholas J Petrelli

36

Nicholas J Petrelli

1 reference

8 January 2018

30

Michal Barzily-Rokni

1 reference

8 January 2018

3

Patricia Brafford

1 reference

8 January 2018

24

Lauren E Haydu

1 reference

8 January 2018

7

Batool Shannan

1 reference

8 January 2018

2

Katrin Sproesser

1 reference

8 January 2018

52

Lynn Schuchter

1 reference

8 January 2018

4

Marilda Beqiri

1 reference

8 January 2018

9

Michela Perego

1 reference

8 January 2018

41

Alexander Roesch

1 reference

8 January 2018

46

Giordano Caponigro

1 reference

8 January 2018

Bradley Garman

5

1 reference

8 January 2018

Min Xiao

6

1 reference

8 January 2018

Andrea Watters

8

1 reference

8 January 2018

Gao Zhang

10

1 reference

8 January 2018

Xiangfan Yin

12

1 reference

8 January 2018

Qin Liu

13

1 reference

8 January 2018

Ioannis N Anastopoulos

14

1 reference

8 January 2018

Bradley Wubbenhorst

15

1 reference

8 January 2018

Melissa A Wilson

16

1 reference

8 January 2018

Wei Xu

17

1 reference

8 January 2018

Michael Feldman

19

1 reference

8 January 2018

Xiaowei Xu

20

1 reference

8 January 2018

Ravi Amaravadi

21

1 reference

8 January 2018

David E Elder

23

1 reference

8 January 2018

Michael A Davies

26

1 reference

8 January 2018

Yiling Lu

27

1 reference

8 January 2018

Dennie T Frederick

29

1 reference

8 January 2018

Dave S Hoon

32

1 reference

8 January 2018

Michael Guarino

33

1 reference

8 January 2018

Joseph J Bennett

34

1 reference

8 January 2018

Randall W Ryan

35

1 reference

8 January 2018

Carol L Shields

37

1 reference

8 January 2018

Mizue Terai

38

1 reference

8 January 2018

Takami Sato

39

1 reference

8 January 2018

Andrew E Aplin

40

1 reference

8 January 2018

David Darr

42

1 reference

8 January 2018

Steve Angus

43

1 reference

8 January 2018

Rakesh Kumar

44

1 reference

8 January 2018

Ensar Halilovic

45

1 reference

8 January 2018

Sebastien Jeay

47

1 reference

8 January 2018

Jens Wuerthner

48

1 reference

8 January 2018

Annette Walter

49

1 reference

8 January 2018

Matthias Ocker

50

1 reference

8 January 2018

Matthew B Boxer

51

1 reference

8 January 2018

publication date

1 November 2017

1 reference

8 January 2018

published in

Cell Reports

1 reference

8 January 2018

volume

21

1 reference

8 January 2018

issue

7

1 reference

8 January 2018

page(s)

1953-1967

1 reference

8 January 2018

Melanoma Brain Metastases: Current Areas of Investigation and Future Directions

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Targeting T Cell Co-receptors for Cancer Therapy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Establishing Human Skin Grafts in Mice as Model for Melanoma Progression

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Recurrent inactivating RASA2 mutations in melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Genomic Classification of Cutaneous Melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Patient-derived xenograft models: an emerging platform for translational cancer research

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Development and function of human innate immune cells in a humanized mouse model

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Signatures of mutational processes in human cancer

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Human melanoma metastasis in NSG mice correlates with clinical outcome in patients

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

A landscape of driver mutations in melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Mutations in GNA11 in uveal melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Selective inhibition of BET bromodomains

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Determinants of survival in patients with brain metastases from cutaneous melanoma

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

MEK1 mutations confer resistance to MEK and B-RAF inhibition

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Efficient tumour formation by single human melanoma cells

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

A tumorigenic subpopulation with stem cell properties in melanomas

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Melanoma incidence and mortality among US whites, 1969-1999.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726788

Heterotransplantation of a human malignant tumour to "Nude" mice

15 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29141225

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.CELREP.2017.10.021

1 reference

8 January 2018

PMC publication ID

5726788

1 reference

8 January 2018

PubMed publication ID

29141225

1 reference

8 January 2018